ClinicalTrials.gg
CompletedNCT01229410Updated Aug 5, 2013Results posted

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

A Phase 1 interventional study of 400 µg Brimonidine Tartrate Implant and 200 µg Brimonidine Tartrate Implant in Vitrectomy, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-05.

Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.

02

Conditions studied

  • Vitrectomy
03

In context

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plan on having a pars plana vitrectomy for repair of a posterior segment condition (eg, epiretinal membrane, macular hole, vitreomacular traction)
  • Visual acuity in the non-study eye better than 20/200

Exclusion criteria

Exclusion Criteria:

  • History of pars plana vitrectomy or retinal detachment surgery in the study eye
  • Surgery or laser treatment in the study eye within 3 months
  • Use of brimonidine, apraclonidine or other topical alpha-2-agonist in either eye within 2 weeks
  • Intraocular infection or inflammation
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    400 µg Brimonidine Tartrate Implant

    400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).

    Drug: 400 µg Brimonidine Tartrate Implant

  • Experimental
    200 µg Brimonidine Tartrate Implant

    200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).

    Drug: 200 µg Brimonidine Tartrate Implant

Interventions

  • 400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).

    Also known as: Brimonidine Tartrate PS DDS®

  • 200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).

    Also known as: Brimonidine Tartrate PS DDS®

06

What researchers measure

Primary outcomes

  1. Highest Vitreous Humor Level of Brimonidine in the Study Eye

    The highest level of brimonidine measured in the vitreous humor of the study eye in any patient is reported for each treatment arm. The vitreous humor is the clear gel that fills the space between the lens and the retina of the eye.

    Time frame: 60 Days

Secondary outcomes

  1. Highest Aqueous Humor Level of Brimonidine in the Study Eye

    The highest level of brimonidine measured in the aqueous humor of the study eye in any patient is reported for each treatment arm. The aqueous humor is the clear fluid in the chamber of the eye between the cornea and the lens.

    Time frame: 60 Days

  2. Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)

    Percentage of patient samples with plasma levels of brimonidine reported as BLQ (i.e., too low to be determined using standard methods). Plasma is the fluid portion of the blood.

    Time frame: 60 Days

07

Results

Posted Aug 5, 2013

Participant flow

Participant flow — Overall Study
Milestone400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate Implant
Started1212
Completed79
Not completed53

Outcome measures

PrimaryHighest Vitreous Humor Level of Brimonidine in the Study Eye

The highest level of brimonidine measured in the vitreous humor of the study eye in any patient is reported for each treatment arm. The vitreous humor is the clear gel that fills the space between the lens and the retina of the eye.

Time frame:
60 Days
Reported as:
Number · Nanogram/milliliter (ng/mL)
Highest Vitreous Humor Level of Brimonidine in the Study Eye
Nanogram/milliliter (ng/mL)400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate Implant
Highest Vitreous Humor Level of Brimonidine in the Study Eye137.034.9
SecondaryHighest Aqueous Humor Level of Brimonidine in the Study Eye

The highest level of brimonidine measured in the aqueous humor of the study eye in any patient is reported for each treatment arm. The aqueous humor is the clear fluid in the chamber of the eye between the cornea and the lens.

Time frame:
60 Days
Reported as:
Number · Nanogram/milliliter (ng/mL)
Highest Aqueous Humor Level of Brimonidine in the Study Eye
Nanogram/milliliter (ng/mL)400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate Implant
Highest Aqueous Humor Level of Brimonidine in the Study Eye17.512.5
SecondaryPercentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)

Percentage of patient samples with plasma levels of brimonidine reported as BLQ (i.e., too low to be determined using standard methods). Plasma is the fluid portion of the blood.

Time frame:
60 Days
Reported as:
Number · Percentage of Patient Samples
Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)
Percentage of Patient Samples400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate Implant
Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)53.372.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 µg Brimonidine Tartrate Implant—1/12 (8.3%)11/12 (91.7%)
200 µg Brimonidine Tartrate Implant—2/12 (16.7%)12/12 (100%)
Most frequent serious events
Most frequent serious events
Event400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate Implant
Choroidal DetachmentEye disorders1/120/12
Atrial FibrillationCardiac disorders1/120/12
Vitreous HaemorrhageEye disorders0/121/12
Retinal DetachmentEye disorders0/121/12
Most frequent other events
Showing 10 of 27
Most frequent other events
Event400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate Implant
Conjunctival HaemorrhageEye disorders7/126/12
Conjunctival HyperaemiaEye disorders5/127/12
Intraocular Pressure IncreasedInvestigations1/123/12
Conjunctival OedemaEye disorders2/122/12
HypertensionVascular disorders2/120/12
Vitreous HaemorrhageEye disorders0/122/12
Retinal DetachmentEye disorders0/122/12
NasopharyngitisInfections and infestations1/121/12
CataractEye disorders1/121/12
Eye PainEye disorders1/121/12

Baseline characteristics

Age Continuous
Age Continuous(Years)400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate ImplantTotal
Mean69.7 ± 2.8766.5 ± 9.6768.1 (53 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate ImplantTotal
Female8614
Male4610
08

Study locations

2 sites
  • Salt Lake City, Utah, United States
  • Prague, Czech Republic
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of May 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2010
First posted
Oct 27, 2010
Start
Dec 2010
Primary completionActual
May 2011
CompletionActual
Oct 2011
Results first posted
Aug 5, 2013
Last update
Aug 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01229410
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 27, 2010
Start date
Dec 2010
Primary completion
May 2011
Completion
Oct 2011
Results posted
Aug 5, 2013
Last update
Aug 5, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion